Lonza’s Cantonese Dream
The Swiss firm continues investment in China with a manufacturing upgrade to its key Guangzhou site
Lonza has upgraded its “Nansha” site, equipping it with a new drug product fill and finish manufacturing line. The level-up is aimed at establishing capacity for clinical trial and commercial supply inside the People’s Republic of China.
Hong Pan, Lonza’s General Manager for China, said, “[The upgrade] not only demonstrates our commitment to the Chinese market but also marks an important milestone in achieving our long-term ambition of increasing drug product capacity and addressing growing customer demand for an end-to-end drug product solution.”
The investment marks the latest chapter in Lonza’s longstanding interest in the Middle Kingdom, which centers around the Nansha site. Nansha opened in 2003 and is located on an island in the Pearl River delta in the southern reaches of Guangzhou.
Seven months prior and 1212 kilometres to the north, Lonza also boosted its presence in Shanghai, opening an office in the fashionable Xintiandi business hub.
Between studying for my English undergrad and Publishing master's degrees I was out in Shanghai, teaching, learning, and getting extremely lost. Now I'm expanding my mind down a rather different rabbit hole: the pharmaceutical industry. Outside of this job I read mountains of fiction and philosophy, and I must say, it's very hard to tell who's sharper: the literati, or the medicine makers.
